Haiti vs Papua New Guinea: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage
Haiti
45.0%
in 2024
Papua New Guinea
41.0%
in 2024
Haiti rank
140th
Papua New Guinea rank
142nd
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage over time
- Haiti
- Papua New Guinea
How they compare
Haiti currently reports 45.0% against 41.0% in Papua New Guinea, a difference of 4.0%.
That makes Haiti's figure about 1.1 times Papua New Guinea's.
The two have swapped places 1 time across 7 shared years of data; in 2018 it was Papua New Guinea ahead.
Haiti ranks 140th and Papua New Guinea ranks 142nd of 146 countries.
Across the 2 decades both report, Haiti averaged higher in 1 and Papua New Guinea in 1.
Head to head by decade
| Decade | Haiti | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 13.5% | 35.0% | 21.5% | Papua New Guinea |
| 2020s | 47.6% | 36.6% | 11.0% | Haiti |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage, Haiti or Papua New Guinea?
- Haiti, at 45.0% against 41.0% in Papua New Guinea as of 2024.
- What is the difference in pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage between Haiti and Papua New Guinea?
- 4.0%, with Haiti ahead.
- How many years of comparable data are there for Haiti and Papua New Guinea?
- 7 years are reported by both, from 2018 to 2024.
- How do Haiti and Papua New Guinea rank globally for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Haiti ranks 140th and Papua New Guinea ranks 142nd of 146 countries.
- Where does this data come from?
- WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.